PMID- 22507564
OWN - NLM
STAT- MEDLINE
DCOM- 20120724
LR  - 20211203
IS  - 1471-2172 (Electronic)
IS  - 1471-2172 (Linking)
VI  - 13
DP  - 2012 Apr 16
TI  - Tissue transglutaminase treatment leads to concentration-dependent changes in 
      dendritic cell phenotype--implications for the role of transglutaminase in 
      coeliac disease.
PG  - 20
LID - 10.1186/1471-2172-13-20 [doi]
AB  - Dendritic cells (DCs) are part of the innate immune system with a key role in 
      initiating and modulating T cell mediated immune responses. Coeliac disease is 
      caused by inappropriate activation of such a response leading to small intestinal 
      inflammation when gluten is ingested. Tissue transglutaminase, an extracellular 
      matrix (ECM) protein, has an established role in coeliac disease; however, little 
      work to date has examined its impact on DCs. The aim of this study was to 
      investigate the effect of small intestinal ECM proteins, fibronectin (FN) and 
      tissue transglutaminase 2 (TG-2), on human DCs by including these proteins in DC 
      cultures.The study used flow cytometry and scanning electron microscopy to 
      determine the effect of FN and TG-2 on phenotype, endocytic ability and and 
      morphology of DCs. Furthermore, DCs treated with FN and TG-2 were cultured with T 
      cells and subsequent T cell proliferation and cytokine profile was determined.The 
      data indicate that transglutaminase affected DCs in a concentration-dependent 
      manner. High concentrations were associated with a more mature phenotype and 
      increased ability to stimulate T cells, while lower concentrations led to 
      maintenance of an immature phenotype.These data provide support for an additional 
      role for transglutaminase in coeliac disease and demonstrate the potential of in 
      vitro modelling of coeliac disease pathogenesis.
FAU - Dalleywater, William J
AU  - Dalleywater WJ
AD  - Allergy and Tissue Modelling Research Group, School of Molecular Medical 
      Sciences, Queen's Medical Centre, The University of Nottingham, A Floor, West 
      Block, Nottingham, NG7 2UH, UK.
FAU - Chau, David Y S
AU  - Chau DY
FAU - Ghaemmaghami, Amir M
AU  - Ghaemmaghami AM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120416
PL  - England
TA  - BMC Immunol
JT  - BMC immunology
JID - 100966980
RN  - 0 (Cytokines)
RN  - 0 (TGM2 protein, human)
RN  - EC 2.3.2.13 (Protein Glutamine gamma Glutamyltransferase 2)
RN  - EC 2.3.2.13 (Transglutaminases)
RN  - EC 3.6.1.- (GTP-Binding Proteins)
SB  - IM
MH  - Celiac Disease/*enzymology/immunology
MH  - Cytokines/metabolism
MH  - Dendritic Cells/*enzymology/immunology
MH  - Endocytosis/drug effects
MH  - GTP-Binding Proteins/*pharmacology
MH  - Humans
MH  - Immunophenotyping
MH  - Lymphocyte Activation/immunology
MH  - *Phenotype
MH  - Protein Glutamine gamma Glutamyltransferase 2
MH  - T-Lymphocytes/immunology
MH  - Transglutaminases/*pharmacology
PMC - PMC3352302
EDAT- 2012/04/18 06:00
MHDA- 2012/07/25 06:00
PMCR- 2012/04/16
CRDT- 2012/04/18 06:00
PHST- 2011/12/15 00:00 [received]
PHST- 2012/04/16 00:00 [accepted]
PHST- 2012/04/18 06:00 [entrez]
PHST- 2012/04/18 06:00 [pubmed]
PHST- 2012/07/25 06:00 [medline]
PHST- 2012/04/16 00:00 [pmc-release]
AID - 1471-2172-13-20 [pii]
AID - 10.1186/1471-2172-13-20 [doi]
PST - epublish
SO  - BMC Immunol. 2012 Apr 16;13:20. doi: 10.1186/1471-2172-13-20.